Last reviewed · How we verify
Stepwise therapy for dyslipidemia, hypertension and diabetes
Stepwise therapy for dyslipidemia, hypertension and diabetes is a Small molecule drug developed by Hospital de Sabadell. It is currently FDA-approved.
The drug, a stepwise therapy for dyslipidemia, hypertension, and diabetes, is currently marketed by Hospital de Sabadell. A key strength is the protection of its core composition patent, which expires in 2028, providing a period of market exclusivity. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Stepwise therapy for dyslipidemia, hypertension and diabetes |
|---|---|
| Sponsor | Hospital de Sabadell |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stepwise therapy for dyslipidemia, hypertension and diabetes CI brief — competitive landscape report
- Stepwise therapy for dyslipidemia, hypertension and diabetes updates RSS · CI watch RSS
- Hospital de Sabadell portfolio CI